Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) FCF Yield % : -1.49 (As of May. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Eucrates Biomedical Acquisition's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $0.00 Mil. Therefore, Eucrates Biomedical Acquisition's FCF Yield % for today is -1.49%.

The historical rank and industry rank for Eucrates Biomedical Acquisition's FCF Yield % or its related term are showing as below:

EUCRU' s FCF Yield % Range Over the Past 10 Years
Min: -1.49 Med: 0 Max: 0
Current: -1.49

EUCRU's FCF Yield % is not ranked
in the Diversified Financial Services industry.
Industry Median: -1.64 vs EUCRU: -1.49

Eucrates Biomedical Acquisition's FCF Margin % for the quarter that ended in Dec. 2022 was 0.00%.

Eucrates Biomedical Acquisition FCF Yield % Historical Data

The historical data trend for Eucrates Biomedical Acquisition's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition FCF Yield % Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

FCF Yield %

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
FCF Yield %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Eucrates Biomedical Acquisition's FCF Yield %

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition's FCF Yield % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's FCF Yield % falls into.

Eucrates Biomedical Acquisition FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Eucrates Biomedical Acquisition's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-0.63	/
	=	N/A%

Eucrates Biomedical Acquisition's annualized FCF Yield % for the quarter that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.391	*	4	/
	=	N/A%

Eucrates Biomedical Acquisition FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Eucrates Biomedical Acquisition FCF Yield % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021